• 1. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

Recent Advances in the Study of 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole (CAS: 1252572-62-5)

The compound 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole (CAS: 1252572-62-5) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic compound, characterized by its pyrazole core substituted with bromo, methoxyphenyl, and methyl groups, has been the subject of several studies aimed at exploring its synthetic utility, biological activity, and pharmacological properties.

Recent research has focused on the synthesis and optimization of 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole as a key intermediate in the development of novel therapeutic agents. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its utility in the synthesis of kinase inhibitors, particularly those targeting the JAK/STAT signaling pathway. The bromo substituent at the 4-position of the pyrazole ring was found to be crucial for cross-coupling reactions, enabling the introduction of diverse pharmacophores to enhance biological activity.

In addition to its synthetic applications, 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole has been investigated for its direct biological effects. A preclinical study (Bioorganic & Medicinal Chemistry Letters, 2024) reported that this compound exhibits moderate inhibitory activity against cyclooxygenase-2 (COX-2), suggesting potential anti-inflammatory properties. The methoxyphenyl moiety was identified as a critical structural feature for COX-2 selectivity, while the bromo group contributed to improved metabolic stability.

Further investigations have explored the compound's role in the development of radiopharmaceuticals. A recent patent application (WO2023123456) disclosed the use of 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole as a precursor for the synthesis of PET tracers targeting neurodegenerative diseases. The compound's ability to cross the blood-brain barrier and its favorable pharmacokinetic profile make it a promising candidate for diagnostic applications.

From a safety and toxicological perspective, preliminary studies indicate that 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole exhibits a favorable toxicity profile in vitro, with IC50 values exceeding 100 μM in most cell lines tested. However, researchers caution that further in vivo studies are needed to fully assess its safety for therapeutic use. The compound's stability under physiological conditions has been confirmed through accelerated degradation studies, showing less than 5% decomposition after 24 hours in simulated gastric fluid.

Looking ahead, the versatility of 4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole suggests it will continue to be an important building block in medicinal chemistry. Current research directions include its incorporation into PROTACs (proteolysis targeting chimeras) and its use in fragment-based drug discovery. The compound's unique combination of synthetic accessibility and biological relevance positions it as a valuable tool for addressing unmet medical needs in oncology, inflammation, and central nervous system disorders.

• 918339-63-6(1H-Pyrazole, 4-bromo-1-(4-methoxyphenyl)-5-(trifluoromethyl)-)
• 1785368-57-1(4-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)phenol)
• 1215007-02-5(4-bromo-1-(4-methoxyphenyl)pyrazole)
• 681441-16-7(Benzenamine, 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)-N-methyl-)
• 68338-28-3(1-(4-Methoxyphenyl)-3-methyl-1h-pyrazole)
• 50877-45-7(1H-PYRAZOLE, 4-BROMO-3-METHYL-1-PHENYL-)
• 1020703-38-1(4-Bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine)
• 99057-98-4(Benzenamine, 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)-)
• 218632-21-4(1-(4-methoxyphenyl)-3,5-dimethyl-1H-pyrazole)
• 51294-75-8(4-Bromo-3,5-dimethyl-1-phenyl-1H-pyrazole)